CAJ | 학술논문

目的探讨Cox-2抑制剂塞来昔布治疗ER、PR阴性表达乳腺癌的治疗效果和安全性。方法将我院2010年和2011年收治的ER、PR阴性表达乳腺癌患者76例随机分为实验组和对照组两组，每组38例。所有患者均采用相同的化疗方案，化疗开始时，实验组患者加用塞来昔布，对照组患者加用三苯氧胺，治疗一年后比较两组的治疗效果、疾病的进展时间及不良反应。结果实验组的治疗总有效率为63.16％，显著高于对照组的39.47％，差异有统计学意义（P<0.05）；实验组的疾病进展时间为（276.9±32.8）天，较对照组（246.1±35.6）明显延长，差异有统计学意义（P<0.05）；两组不良反应的发生率比较，差异有统计学意义（P<0.05）。结论与三苯氧胺比较，塞来昔布能有效提高ER、PR阴性表达乳腺癌的治疗效果，延缓病情进展，值得临床进一步研究。
목적탐토Cox-2억제제새래석포치료ER、PR음성표체유선암적치료효과화안전성。방법장아원2010년화2011년수치적ER、PR음성표체유선암환자76례수궤분위실험조화대조조량조，매조38례。소유환자균채용상동적화료방안，화료개시시，실험조환자가용새래석포，대조조환자가용삼분양알，치료일년후비교량조적치료효과、질병적진전시간급불량반응。결과실험조적치료총유효솔위63.16％，현저고우대조조적39.47％，차이유통계학의의（P<0.05）；실험조적질병진전시간위（276.9±32.8）천，교대조조（246.1±35.6）명현연장，차이유통계학의의（P<0.05）；량조불량반응적발생솔비교，차이유통계학의의（P<0.05）。결론여삼분양알비교，새래석포능유효제고ER、PR음성표체유선암적치료효과，연완병정진전，치득림상진일보연구。
Objective To observe the clinical efficacy of Cox-2 inhibitors (Celecoxib) in the treatment of ER, PR nega-tive breast cancer. Methods 76 cases of breast cancer with negative expression of ER and PR admitted in our hospital in 2010 and 2011 were collected and randomly divided into two groups, 38 cases in each group. All the patients were treated with the same chemotherapy. From the beginning of chemotherapy, the experimental group was further treated with Celecoxib, while the control group was further treated with tamoxifen. The time of disease progression, treatment effect and adverse reactions were compared between the two groups one year later. Results The total effective rate of experimental group was 63.16%, which was significantly higher than that of the control group (39.47%, P<0.05); the time of progression of disease in experimental group and control group were respectively 276.9±32.8 and 246.1±35.6 days, which was significantly longer in the experimental group (P<0.05); there were significant differences in adverse reactions between two groups (P<0.05). Conclusion Compared with tamoxifen, celeCoxib could effectively improve the clinical efficacy and prolong the survival time of breast cancer patients with negative expression of ER and PR, therefore, it is worthy of further research.